ObsEva racks up $60 mln Series B

By Iris Dorbian — 3 months ago

Swiss biopharmaceutical company ObsEva, a developer of drugs that focus on “serious conditions compromising pregnancy from conception to birth,” has raised $60 million in Series B funding. The investors included HBM Healthcare Investments, New Enterprise Associates, OrbiMed, Rock Springs Capital, Sofinnova Partners, Sofinnova Ventures, Novo Ventures and MS Ventures. In addition to the funding, Ed Mathers of NEA has been added to ObsEva’s board of directors. Leerink Partners LLC was the advisor on the funding.

Continue

GSK buys GlycoVaxyn for $212 mln

By Luisa Beltran — 12 months ago

Sofinnova Partners has sold GlycoVaxyn to GlaxoSmithKline for $212 million. Schlieren, Switzerland-based GlycoVaxyn develops conjugate vaccines to treat bacterial infections. GSK was a minority investor of GlycoVaxyn.

Continue

Green Biologics fetches $76 mln

By Iris Dorbian — 1 year ago

UK-based renewable chemicals firm Green Biologics has raised $42 million in equity funding. Swire Pacific Limited and Sofinnova Partners led the round with participation from return backers Capricorn Venture Partners, Oxford Capital Partners, Morningside Technology Partners and ConvergInce Holdings LLC. Also, Green Biologics has received $34 million in mostly debt funding led by Tennenbaum Capital Partners.

Continue

VC-backed RefleXion Medical hires new VP of engineering

By Iris Dorbian — 2 years ago

RefleXion Medical has named David Q. Larkin as vice president of engineering. Previously, Larkin worked at Intuitive Surgical where he most recently served as vice president of engineering. Based in Burlingame, Calif., RefleXion Medical is a medical device company developing a biologically-guided radiation therapy system for cancer treatment. It is backed by Sofinnova Partners, Pfizer Venture Investments and Venrock.

Continue

Pixium Vision launches IPO on Euronext Paris

By Angela Sormani — 2 years ago

Pixium Vision has launched its Initial Public Offering on Euronext’s regulated market in Paris. Based in Paris, Pixium is a maker of vision restoration systems for the blind. Its backers include Sofinnova Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Bpifrance, Seventure and Polytechnos.

Continue

NuCana grabs $57 mln Series B funds

By Iris Dorbian — 2 years ago

NuCana has raised $57 million in Series B funding. Sofinnova Ventures led the round with participation from Sofinnova Partners, Morningside Ventures, Alida Capital International and the Scottish Investment Bank, the investment arm of Scottish Enterprise. In addition to the funding, James Healy and Gerald Chan, co-founder and chairman of Morningside Ventures respectively, have been added to NuCana’s board of directors. Based in Edinburgh, NuCana is an biopharmaceutical firm focused on anti-cancer medicines.

Continue

Pixium hires new CEO and director

By Iris Dorbian — 2 years ago

Pixium has appointed Khalid Ishaque as CEO and director. Previously, Ishaque worked at Boston Scientific where he most recently served as general manager of its neuromodulation international business. Based in Paris, Pixium is a maker of vision restoration systems for the blind. Its backers include Sofinnova Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Bpifrance, Seventure and Polytechnos.

Continue

Pixium Vision raises funds led by Sofinnova

By Angela Sormani — 2 years ago

Pixium Vision, a developer of innovative retinal implant systems, has closed a Series A extension financing. This round was led by Sofinnova Partners, with support from Bpifrance, through the InnoBio fund, and existing series A investors Omnes Capital and Abingworth. In conjunction with the financing, Antoine Papiernik at Sofinnova Partners and Chahra Louafi at Bpifrance have joined the Pixium board of directors.

Continue

InnoBio Gets Backing

By Angela Sormani — 3 years ago

InnoBio, a biotech fund managed by CDC Entreprises, and Sofinnova Partners have announced a joint investment in MedDay for 8 million euros ($10.5 million). Created in 2011 by Dr Frédéric Sedel and Dr Guillaume Brion, MedDay is specialised in the treatment of neuro-metabolic diseases.

Continue